|
Gene: HRAS |
Gene summary for HRAS |
Gene summary. |
Gene information | Species | Human | Gene symbol | HRAS | Gene ID | 3265 |
Gene name | HRas proto-oncogene, GTPase | |
Gene Alias | C-BAS/HAS | |
Cytomap | 11p15.5 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P01112 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3265 | HRAS | GSM4909298 | Human | Breast | IDC | 4.62e-07 | 3.06e-01 | 0.1551 |
3265 | HRAS | GSM4909311 | Human | Breast | IDC | 2.54e-05 | -1.07e-01 | 0.1534 |
3265 | HRAS | GSM4909312 | Human | Breast | IDC | 3.50e-04 | -1.42e-01 | 0.1552 |
3265 | HRAS | GSM4909317 | Human | Breast | IDC | 3.51e-16 | 4.63e-01 | 0.1355 |
3265 | HRAS | GSM4909318 | Human | Breast | IDC | 3.47e-09 | 7.39e-01 | 0.2031 |
3265 | HRAS | GSM4909319 | Human | Breast | IDC | 1.74e-05 | -1.37e-02 | 0.1563 |
3265 | HRAS | GSM4909321 | Human | Breast | IDC | 4.73e-03 | 1.28e-01 | 0.1559 |
3265 | HRAS | brca1 | Human | Breast | Precancer | 2.78e-11 | 3.86e-01 | -0.0338 |
3265 | HRAS | brca2 | Human | Breast | Precancer | 2.43e-02 | 1.74e-01 | -0.024 |
3265 | HRAS | DCIS2 | Human | Breast | DCIS | 5.63e-42 | 1.71e-01 | 0.0085 |
3265 | HRAS | LZE2T | Human | Esophagus | ESCC | 4.37e-02 | 2.43e-01 | 0.082 |
3265 | HRAS | LZE4T | Human | Esophagus | ESCC | 1.47e-03 | 7.33e-02 | 0.0811 |
3265 | HRAS | LZE7T | Human | Esophagus | ESCC | 1.14e-06 | 2.48e-01 | 0.0667 |
3265 | HRAS | LZE20T | Human | Esophagus | ESCC | 9.21e-07 | 2.90e-01 | 0.0662 |
3265 | HRAS | LZE24T | Human | Esophagus | ESCC | 1.37e-06 | 1.13e-01 | 0.0596 |
3265 | HRAS | LZE21T | Human | Esophagus | ESCC | 6.03e-07 | 3.30e-01 | 0.0655 |
3265 | HRAS | P1T-E | Human | Esophagus | ESCC | 4.21e-10 | 5.91e-01 | 0.0875 |
3265 | HRAS | P2T-E | Human | Esophagus | ESCC | 1.22e-36 | 7.43e-01 | 0.1177 |
3265 | HRAS | P4T-E | Human | Esophagus | ESCC | 4.87e-45 | 1.03e+00 | 0.1323 |
3265 | HRAS | P5T-E | Human | Esophagus | ESCC | 3.56e-37 | 7.55e-01 | 0.1327 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
GO:00514029 | Breast | Precancer | neuron apoptotic process | 38/1080 | 246/18723 | 2.68e-08 | 1.75e-06 | 38 |
GO:00513468 | Breast | Precancer | negative regulation of hydrolase activity | 50/1080 | 379/18723 | 3.85e-08 | 2.34e-06 | 50 |
GO:19012149 | Breast | Precancer | regulation of neuron death | 41/1080 | 319/18723 | 1.27e-06 | 4.80e-05 | 41 |
GO:00435237 | Breast | Precancer | regulation of neuron apoptotic process | 31/1080 | 212/18723 | 1.69e-06 | 6.08e-05 | 31 |
GO:00018196 | Breast | Precancer | positive regulation of cytokine production | 52/1080 | 467/18723 | 4.18e-06 | 1.29e-04 | 52 |
GO:00420609 | Breast | Precancer | wound healing | 48/1080 | 422/18723 | 5.48e-06 | 1.63e-04 | 48 |
GO:00075688 | Breast | Precancer | aging | 41/1080 | 339/18723 | 5.95e-06 | 1.71e-04 | 41 |
GO:00487329 | Breast | Precancer | gland development | 49/1080 | 436/18723 | 6.11e-06 | 1.73e-04 | 49 |
GO:00103323 | Breast | Precancer | response to gamma radiation | 13/1080 | 56/18723 | 1.35e-05 | 3.38e-04 | 13 |
GO:00506736 | Breast | Precancer | epithelial cell proliferation | 46/1080 | 437/18723 | 6.02e-05 | 1.23e-03 | 46 |
GO:00093148 | Breast | Precancer | response to radiation | 47/1080 | 456/18723 | 8.39e-05 | 1.62e-03 | 47 |
GO:00712147 | Breast | Precancer | cellular response to abiotic stimulus | 37/1080 | 331/18723 | 9.12e-05 | 1.73e-03 | 37 |
GO:01040047 | Breast | Precancer | cellular response to environmental stimulus | 37/1080 | 331/18723 | 9.12e-05 | 1.73e-03 | 37 |
GO:19049519 | Breast | Precancer | positive regulation of establishment of protein localization | 36/1080 | 319/18723 | 9.30e-05 | 1.75e-03 | 36 |
GO:00018898 | Breast | Precancer | liver development | 21/1080 | 147/18723 | 1.08e-04 | 1.96e-03 | 21 |
GO:00329709 | Breast | Precancer | regulation of actin filament-based process | 42/1080 | 397/18723 | 1.11e-04 | 2.01e-03 | 42 |
GO:00514959 | Breast | Precancer | positive regulation of cytoskeleton organization | 28/1080 | 226/18723 | 1.13e-04 | 2.04e-03 | 28 |
GO:00102125 | Breast | Precancer | response to ionizing radiation | 21/1080 | 148/18723 | 1.19e-04 | 2.13e-03 | 21 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501053 | Breast | DCIS | Alzheimer disease | 105/846 | 384/8465 | 3.23e-23 | 1.49e-21 | 1.10e-21 | 105 |
hsa0471453 | Breast | DCIS | Thermogenesis | 74/846 | 232/8465 | 8.72e-21 | 3.13e-19 | 2.30e-19 | 74 |
hsa0502253 | Breast | DCIS | Pathways of neurodegeneration - multiple diseases | 114/846 | 476/8465 | 4.74e-20 | 1.53e-18 | 1.13e-18 | 114 |
hsa0513253 | Breast | DCIS | Salmonella infection | 55/846 | 249/8465 | 8.71e-09 | 1.87e-07 | 1.38e-07 | 55 |
hsa0491552 | Breast | DCIS | Estrogen signaling pathway | 35/846 | 138/8465 | 1.40e-07 | 2.51e-06 | 1.85e-06 | 35 |
hsa0421854 | Breast | DCIS | Cellular senescence | 34/846 | 156/8465 | 8.53e-06 | 1.06e-04 | 7.80e-05 | 34 |
hsa0520552 | Breast | DCIS | Proteoglycans in cancer | 39/846 | 205/8465 | 5.36e-05 | 5.58e-04 | 4.11e-04 | 39 |
hsa0413752 | Breast | DCIS | Mitophagy - animal | 17/846 | 72/8465 | 5.75e-04 | 4.42e-03 | 3.26e-03 | 17 |
hsa0491932 | Breast | DCIS | Thyroid hormone signaling pathway | 23/846 | 121/8465 | 1.78e-03 | 1.22e-02 | 9.00e-03 | 23 |
hsa0541754 | Breast | DCIS | Lipid and atherosclerosis | 34/846 | 215/8465 | 4.50e-03 | 2.46e-02 | 1.82e-02 | 34 |
hsa0517034 | Breast | DCIS | Human immunodeficiency virus 1 infection | 33/846 | 212/8465 | 6.49e-03 | 3.22e-02 | 2.37e-02 | 33 |
hsa0481033 | Breast | DCIS | Regulation of actin cytoskeleton | 35/846 | 229/8465 | 6.89e-03 | 3.37e-02 | 2.48e-02 | 35 |
hsa0521133 | Breast | DCIS | Renal cell carcinoma | 14/846 | 69/8465 | 7.42e-03 | 3.48e-02 | 2.56e-02 | 14 |
hsa0414417 | Breast | DCIS | Endocytosis | 37/846 | 251/8465 | 9.92e-03 | 4.40e-02 | 3.24e-02 | 37 |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa05208211 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HRAS | SNV | Missense_Mutation | rs104894228 | c.37N>C | p.Gly13Arg | p.G13R | P01112 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
HRAS | SNV | Missense_Mutation | rs121913233 | c.182A>T | p.Gln61Leu | p.Q61L | P01112 | protein_coding | deleterious(0) | possibly_damaging(0.577) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
HRAS | SNV | Missense_Mutation | rs121913233 | c.182A>T | p.Gln61Leu | p.Q61L | P01112 | protein_coding | deleterious(0) | possibly_damaging(0.577) | TCGA-BH-A0HL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
HRAS | SNV | Missense_Mutation | rs104894230 | c.35G>A | p.Gly12Asp | p.G12D | P01112 | protein_coding | deleterious(0) | benign(0.339) | TCGA-LL-A740-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
HRAS | SNV | Missense_Mutation | rs104894229 | c.34G>T | p.Gly12Cys | p.G12C | P01112 | protein_coding | deleterious(0.04) | benign(0.385) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
HRAS | SNV | Missense_Mutation | novel | c.269T>G | p.Phe90Cys | p.F90C | P01112 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HRAS | SNV | Missense_Mutation | c.388N>A | p.Ala130Thr | p.A130T | P01112 | protein_coding | deleterious(0) | possibly_damaging(0.752) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
HRAS | SNV | Missense_Mutation | rs104894229 | c.34N>A | p.Gly12Ser | p.G12S | P01112 | protein_coding | deleterious(0.02) | benign(0.383) | TCGA-ZJ-AAXF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HRAS | SNV | Missense_Mutation | c.404G>A | p.Arg135Gln | p.R135Q | P01112 | protein_coding | tolerated(0.17) | benign(0.082) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
HRAS | SNV | Missense_Mutation | rs142218590 | c.506G>A | p.Arg169Gln | p.R169Q | P01112 | protein_coding | tolerated(0.28) | benign(0) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3265 | HRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, ENZYME | Pz-1 | 26126987 | ||
3265 | HRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, ENZYME | MEK INHIBITOR PD0325901 | 26544513 | ||
3265 | HRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, ENZYME | Sirolimus | SIROLIMUS | 26882569 | |
3265 | HRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, ENZYME | Selumetinib | SELUMETINIB | 26544513,27222538 | |
3265 | HRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, ENZYME | BRYOSTATIN-1 | 16483930 | ||
3265 | HRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, ENZYME | rigosertib | RIGOSERTIB | 27104980 | |
3265 | HRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, ENZYME | VIRAL VECTOR | 10911621 | ||
3265 | HRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, ENZYME | REOLYSIN | PELAREOREP | ||
3265 | HRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, ENZYME | Everolimus | EVEROLIMUS | 26544513 | |
3265 | HRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, ENZYME | LAK | 3489774 |
Page: 1 2 3 4 5 6 7 |